Holen Sie sich die Stockscreener-App
21.45
4.94%
1.01
Vorhandelsmarkt:
21.26
-0.19
-0.89%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$20.44
Offen:
$20.41
24-Stunden-Volumen:
2.59M
Relative Volume:
1.25
Marktkapitalisierung:
$1.45B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-10.26
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
+7.63%
1M Leistung:
+31.03%
6M Leistung:
-4.41%
1J Leistung:
-36.56%
1-Tages-Spanne:
$20.27
$22.09
1-Wochen-Bereich:
$19.70
$22.09
52-Wochen-Spanne:
$9.98
$38.28
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
21.45 | 1.39B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now - Yahoo Finance
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - Eastern Progress
Tandem Diabetes Care Appoints Sandra Beaver to Board - MSN
How Tandem Diabetes Care Inc. stock valuations compare to rivalsTrade Entry Report & Free Daily Entry Point Trade Alerts - Newser
Is Tandem Diabetes Care Inc. (TD5A) stock resilient in recession scenariosJuly 2025 Trade Ideas & Safe Capital Growth Plans - Newser
Taking Stock of Tandem Diabetes Care (TNDM) Valuation After Fresh Analyst Upgrades and Reaffirmed Optimism - simplywall.st
DelveInsight expects the Artificial Pancreas Device Market to grow at a CAGR of 16.33% through 2032 - The Globe and Mail
Tandem Diabetes (TNDM) Stock Is Up, What You Need To Know - Finviz
Will Tandem Diabetes Care Inc. (TD5A) stock outperform value peersTrade Analysis Report & Growth Oriented Trade Recommendations - Newser
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Tandem Diabetes Care Stock Gains After Analyst Raises Target to $23News and Statistics - IndexBox
Why Tandem Diabetes Care Inc. (TD5A) stock could be top winnerM&A Rumor & Safe Entry Zone Identification - Newser
TNDM SEC FilingsTandem Diabetes 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Tandem Diabetes Care’s (TNDM) Valuation After Legal Probe and t:slim X2 Pump Correction Announcement - Yahoo Finance
TNDM: Morgan Stanley Raises Price Target Amidst Maintained Ratin - GuruFocus
How Tandem Diabetes Care Inc. (TD5A) stock reacts to Fed tightening2025 AllTime Highs & Low Drawdown Investment Strategies - Newser
Free cash flow per share of Tandem Diabetes Care, Inc. – LSE:0M0F - TradingView
(TNDM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Recent Product Correction and Legal Inquiry May Impact Tandem Diabetes Care’s (TNDM) Investment Outlook - Sahm
Risk Check: What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsQuarterly Trade Summary & Weekly High Return Forecasts - moha.gov.vn
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
What risks investors should watch in Tandem Diabetes Care Inc. stockPortfolio Update Report & Verified Short-Term Plans - BỘ NỘI VỤ
A Fresh Look at Tandem Diabetes Care (TNDM) Valuation Following Insulin Pump Device Correction News - Sahm
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
[Form 3] TANDEM DIABETES CARE INC Initial Statement of Beneficial Ownership - Stock Titan
Implantable Insulin Pumps Market Size to Hit USD 14.27 Billion by 2034 - Precedence Research
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), ... - Bakersfield.com
Tandem Diabetes Care Shows Market Leadership With Jump To 83 RS Rating - MSN
Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next - Sahm
Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know - Yahoo Finance
Tandem Diabetes Care, Inc.Common Stock (NQ: TNDM - Markets Financial Content
Momentum Stocks November 2025: Tandem Diabetes Sell, Vicor & Cardinal Health BuyNews and Statistics - IndexBox
Why Tandem Diabetes Care Inc. stock is trending among retail tradersTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Tandem Diabetes Care Inc. (TD5A) stock a momentum leaderLayoff News & Verified Momentum Stock Alerts - newser.com
Why millennials buy Tandem Diabetes Care Inc. (TD5A) stockJuly 2025 Gainers & Consistent Income Trade Ideas - newser.com
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
Can Tandem Diabetes Care Inc. stock deliver surprise earnings beatQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
(TNDM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
VP Hansen Acquires 1,965 Of Tandem Diabetes Care Inc [TNDM] - TradingView
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):